Paste Abstract text here

Table of contents

  • Coronavirus COVID-19 - Executive Insights - Hospitalized COVID-19 Executive Insights

Author(s): Sonal Divekar; Raina Priyadarshini, Ph.D.

Sonal Divekar is an analyst on DRG’s Infectious, Niche & Rare Diseases team, covering diverse indications across the niche & rare portfolio. Prior to this role, she was working as a Senior Analyst at Merck’s Global Centre for Analytics and Forecasting. Her role focused on creating Long Range Forecasts and Demand Forecasts for therapeutic areas like Diabetes and Immunology for the European market. She holds a Master’s degree in Marketing Management from Symbiosis Institute of Business Management, India and a Master’s degree in Microbiology from Pune University, India.

Raina Priyadarshini, Ph.D., is a senior analyst on the Infectious, Niche, and Rare Diseases team at DRG, part of Clarivate. Prior to joining DRG, she was an analyst in the biopharmaceutical industry, where she developed novel disease target-drug combinations for rare CNS and hematological disorders. Dr. Priyadarshini trained as a molecular biologist; her research focused on the interplay between tumor suppressor proteins and oncoproteins. She obtained her doctorate from the National Institute of Immunology.